Targeted Therapeutics Market Revenue to Attain USD 146.32 Bn by 2033
Published: 25 Mar 2025
Author: Precedence Research
Targeted Therapeutics Market Revenue and Trends 2025 to 2033
The global targeted therapeutics market revenue reached USD 85.75 billion in 2025 and is predicted to attain around USD 146.32 billion by 2033 with a CAGR of 6.83%. The demand for targeted therapeutics is increasing due to the surge in the prevalence of cancer, leukemia, and lymphoma.
Market Overview
Targeted therapeutics or targeted therapy is a kind of medical treatment created to specifically attack and target cancer cells while decreasing the damage to healthy normal cells. This approach is crucial to precision medications, which cater to treatment based on the genetic profile of an individual's cancer. These therapies have a higher level of precision, hence causing less harm to healthy cells and offering improved efficiency and better treatment outcomes.
Report Highlights
- By type, the monoclonal antibodies segment dominated the market in 2024. The dominance of the segment can be attributed to the fewer side effects of this therapy as compared to conventional chemotherapy used in cancer treatment. The small molecule segment is expected to grow at the fastest rate over the forecast period. The growth of the segment can be linked to its efficacy in targeting specific cancer cells.
- By application, the lung cancer segment led the market in 2024. The dominance of the segment can be credited to the rising cases of lung cancer across the globe associated with potential death. The breast cancer segment is anticipated to grow at the fastest rate over the projected period. The growth of the segment is due to the surge in cases of breast cancer across the globe among the female population.
- By distribution channel, in 2024, the hospital pharmacies segment held the largest market share. The dominance of the segment can be driven by the growing expenditure of private and public organizations to innovate the hospital infrastructure. The online pharmacies segment is expected to show the fastest growth during the foreseeable future, owing to the rising adoption of smartphones globally.
Market Trends
Surge in Contraceptive Injectable
In recent years, the use of injectable contraceptives has risen significantly. This is mostly due to their high efficacy. These contraceptives can be administered once a month or every three months and are also considered the safest ways to prevent unwanted pregnancy. Also, some injectables like Noristerat a very common in the country like the U.K. and the U.S., impacting positive market growth further.
Development of Biologics Sector
The development of the biologics sector is the major trend in the market, fuelling its growth. A main factor responsible for this is the growing demand for insulin, vaccines, modern medicines, and human growth hormones that are utilized to treat chronic diseases such as cancer. Furthermore, these biologics are mainly taken through the injectable route. Hence, this sudden surge in the biologics sector is driving market expansion.
Increasing Demand for Personalized Medicine
There is an increasing demand for personalized medicine in disease treatment, where therapies are catered to a patient's specific molecular profile. Small molecule therapies provide the potential for more accurate and personalized treatment options, by addressing the special properties of everyone.
Growing Demand for Effective Cancer Treatment
The market is being driven by many factors, one of which is a rise in demand for more efficient treatments for many disorders. Conditions such as genetic disorders, cancer, and autoimmune diseases have a substantial impact on a patient's quality of life and health. Hence targeted therapy has the potential to treat chronic diseases, also resulting in fewer side effects.
Regional Insights
North America dominated the market in 2024. The dominance of the region can be attributed to the ongoing surge in the biologics industry along with the presence of major biotechnology companies in the region. Furthermore, increasing investment and government support to expand production facilities of biopharmaceutical is expected to drive demand for biologics in countries like the U.S. and Canada, thereby fuelling market growth. The major players in the regional market include Abbott Laboratories, GlaxoSmithKline plc., AVEO Pharmaceuticals, Inc., Merck Sharp & Dohme Corp, and Johnson & Johnson Services, Inc.
Asia Pacific is expected to grow at the fastest rate over the forecast period. The growth of the region can be credited to the rising consumer awareness regarding the availability of targeted therapies and the growing incidence of chronic diseases such as cancer. Moreover, the ongoing expansion of medical facilities and the increasing popularity of health insurance will likely boost market growth shortly.
Targeted Therapeutics Market Coverage
| Report Attribute | Key Statistics |
| Market Revenue in 2025 | USD 85.75 Billion |
| Market Revenue by 2033 | USD 146.32 Billion |
| CAGR | 6.83% from 2025 to 2033 |
| Quantitative Units | Revenue in USD million/billion, Volume in units |
| Largest Marke | North America |
| Base Year | 2024 |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Market News
- In January 2024, Remix Therapeutics started a strategic collaboration with Roche, which is pointed toward utilizing RNA modulation for novel drug discovery efforts.
- In October 2023, Medilink Therapeutics uncovered a strategic collaboration and overall license agreement with BioNTech to advance the improvement of the cutting-edge enemy of cancer antibody drug forms.
- In July 2023, PEGylated liposomes incorporating the CREKA concentrated on moiety are diagnosed as recovery dealers, particularly in experimental fashions with excessive metastatic capability. CREKA is uniquely centered on the tumor-related extracellular matrix (ECM) determined in each primary and metastatic tumor location.
Targeted Therapeutics Market Key Players
- Pfizer, Inc.
- AstraZeneca Plc.
- Amgen, Inc.
- F. Hoffmann-La Roche & Co.
- Genentech, Inc.
- Agenus, Inc.
- Celdara Medical LLC
- Arcus Biosciences, Inc.
- Aurinia Pharmaceuticals Inc.
- Gilead Sciences, Inc.
- Serena Therapeutics Inc.
- Nektar Therapeutics Inc.
Market Segmentation
By Type
- Monoclonal Antibodies
- Small Molecule
By Application
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Renal Cancer
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/1358
You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com| +1 804 441 9344